Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland
Background: Following the spread of the coronavirus disease 2019 (COVID-19) pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of trials,...
Similar Items
-
Multifocal multisystem Langerhans cell histiocytosis
by: Anupam Das, et al.
Published: (2017-01-01) -
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN: DIAGNOSTIC MARKERS AND FEATURES OF PHARMACOTHERAPY
by: M.V. Кhaitovych, et al.
Published: (2021-03-01) -
Multisystem atrophy: clinical manifestations, pathogenesis questions
by: T. A. Valikova, et al.
Published: (2010-08-01) -
Researching Multisystemic Resilience: A Sample Methodology
by: Michael Ungar, et al.
Published: (2021-01-01) -
Two adult cases of multisystem inflammatory syndrome associated with SARS-CoV-2
by: Karolina Mieczkowska, BS, et al.
Published: (2021-04-01)